Hepatitis C

[1]  G. Dore,et al.  1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY , 2013 .

[2]  A. Lok,et al.  1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC) , 2013 .

[3]  D. Samuel,et al.  Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. , 2014, Journal of hepatology.

[4]  S. Holmberg,et al.  Evolving epidemiology of hepatitis C virus in the United States. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  T. Asselah,et al.  Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial , 2013, Hepatology.

[6]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[7]  J. Mallolas,et al.  O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY , 2014 .

[8]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[9]  David A. Rolls,et al.  Hepatitis C transmission and treatment as prevention - The role of the injecting network. , 2015, The International journal on drug policy.

[10]  E. Schiff,et al.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence , 2016, Hepatology.

[11]  G. Dore,et al.  Hepatitis C treatment as prevention: evidence, feasibility, and challenges. , 2016, The lancet. Gastroenterology & hepatology.

[12]  Ibrahim Abubakar,et al.  Impact of Hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive to contact network structure , 2017, Scientific Reports.

[13]  D. Subirá,et al.  According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity , 2017, Journal of Virology.

[14]  D. D. Des Jarlais,et al.  Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis , 2017, International journal of STD & AIDS.

[15]  M. Manns,et al.  Extrahepatic morbidity and mortality of chronic hepatitis C. , 2015, Gastroenterology.

[16]  H. Parge,et al.  The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.

[17]  M. Sulkowski.  Current management of hepatitis C virus infection in patients with HIV co-infection. , 2013, The Journal of infectious diseases.

[18]  T. Hassanein,et al.  Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial , 2013, The Lancet.

[19]  M. Charlton.  Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents — A potentially lethal cocktail , 2011, Hepatology.

[20]  P. Simmonds,et al.  Genetic diversity and evolution of hepatitis C virus--15 years on. , 2004, The Journal of general virology.

[21]  P. Sax,et al.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.

[22]  A. Hill,et al.  The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries , 2017, Journal of virus eradication.

[23]  Y. Raji,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options , 2016 .

[24]  J. Rockstroh,et al.  Managing HIV/hepatitis C co-infection in the era of direct acting antivirals , 2013, BMC Medicine.

[25]  V. de Lédinghen,et al.  Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. , 2014, Gastroenterology.

[26]  E. Schiff,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.

[27]  G. Saade,et al.  Hepatitis C in Pregnancy , 2007, American journal of perinatology.

[28]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[29]  S. Lingala,et al.  Natural History of Hepatitis C. , 2015, Gastroenterology clinics of North America.

[30]  P. Lemey,et al.  Genetic History of Hepatitis C Virus in East Asia , 2008, Journal of Virology.

[31]  J. Macías,et al.  Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus , 2009, Hepatology.

[32]  P. Klenerman,et al.  Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection , 2011, Gut.

[33]  K. Amr,et al.  Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention , 2016, World journal of hepatology.

[34]  Charles A. Lesburg,et al.  Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site , 1999, Nature Structural Biology.

[35]  R. Facchetti,et al.  Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. , 2016, Journal of hepatology.

[36]  P. Pockros,et al.  HCV RNA Viral Load Assessments in the Era of Direct-Acting Antivirals , 2013, The American Journal of Gastroenterology.

[37]  G. Missale,et al.  Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments , 2016, Oncoimmunology.

[38]  M. Manns,et al.  Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial , 2014, The Lancet.

[39]  X. Forns,et al.  Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. , 2017, Journal of hepatology.

[40]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[41]  Barbara Rehermann,et al.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.

[42]  A. Hogewoning,et al.  Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.

[43]  C. Rice,et al.  Identification of Rodent Homologs of Hepatitis C Virus and Pegiviruses , 2013, mBio.

[44]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[45]  P. Easterbrook,et al.  Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples – a systematic review and meta-analysis , 2017, BMC Infectious Diseases.

[46]  C. Rouzioux,et al.  Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy , 2006, AIDS.

[47]  S. Pol,et al.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment , 2017, The New England journal of medicine.

[48]  L. Abu-Raddad,et al.  Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  Anne M Johnson,et al.  Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours , 2007, AIDS.

[50]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[51]  J. Poirier,et al.  Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results , 2013, AIDS.

[52]  B. Rehermann,et al.  Hepatitis C virus infection: when silence is deception. , 2003, Trends in immunology.

[53]  J. Dubuisson,et al.  Virus‐neutralizing antibodies to hepatitis C virus , 2013, Journal of viral hepatitis.

[54]  T. Asselah,et al.  O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY , 2014 .

[55]  Wilkins. Unauth.  Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference , 2011 .

[56]  F. Castelli,et al.  Chronic HCV infection: epidemiological and clinical relevance , 2012, BMC Infectious Diseases.

[57]  M. Manns,et al.  Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. , 2017, The Lancet. Infectious diseases.

[58]  M. Manns,et al.  Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  M. Buti,et al.  A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[60]  C. Tovo,et al.  Progression of liver fibrosis in monoinfected patients by hepatitis C virus and coinfected by HCV and human immunodeficiency virus. , 2013, Arquivos de gastroenterologia.

[61]  E. Operskalski,et al.  HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies , 2011, Current HIV/AIDS reports.

[62]  Charles M. Rice,et al.  Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus , 2012, Proceedings of the National Academy of Sciences.

[63]  B. Gazzard,et al.  Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM , 2013, AIDS.

[64]  M. Buti,et al.  Faldaprevir and deleobuvir for HCV genotype 1 infection. , 2013, The New England journal of medicine.

[65]  J.,et al.  The New England Journal of Medicine , 2012 .

[66]  Thomas Berg,et al.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.

[67]  D. Samuel,et al.  Optimum timing of treatment for hepatitis C infection relative to liver transplantation. , 2016, The lancet. Gastroenterology & hepatology.

[68]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[69]  B. McMahon,et al.  Risk of end‐stage liver disease, hepatocellular carcinoma, and liver‐related death by fibrosis stage in the hepatitis C Alaska Cohort , 2017, Hepatology.

[70]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[71]  P. Hill,et al.  Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? , 2017, Globalization and Health.

[72]  P. Marcellin,et al.  Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin , 2012, Hepatology.

[73]  L. Valiquette,et al.  Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010 , 2014, PloS one.

[74]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .

[75]  William J. Rice,et al.  Ultrastructural analysis of hepatitis C virus particles , 2013, Proceedings of the National Academy of Sciences.

[76]  G. Klintmalm,et al.  The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[77]  A. Branch,et al.  Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  L. Abu-Raddad,et al.  Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention , 2017, Journal of viral hepatitis.

[79]  E. Daar,et al.  Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  T. Asselah,et al.  Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. , 2016, The Lancet. Infectious diseases.

[81]  G. Everson,et al.  Drug–drug interactions during antiviral therapy for chronic hepatitis C , 2013, Nature Reviews Gastroenterology &Hepatology.

[82]  P. Klenerman,et al.  Vaccination for hepatitis C virus: closing in on an evasive target , 2011, Expert review of vaccines.

[83]  D. Samuel,et al.  International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES. , 2017, Transplantation.

[84]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[85]  V. de Lédinghen,et al.  Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. , 2009, Journal of hepatology.

[86]  E. Gane,et al.  O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY , 2014 .

[87]  C. Tural,et al.  The natural history of liver cirrhosis in HIV–hepatitis C virus-coinfected patients , 2011, AIDS.

[88]  Salim I. Khakoo,et al.  HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection , 2004, Science.

[89]  G. Foster,et al.  Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing , 2010, Transfusion.

[90]  C. Hézode.  Pan‐genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high‐ and low‐income regions , 2017, Journal of viral hepatitis.

[91]  L. Abu-Raddad,et al.  Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions , 2018, Scientific Reports.

[92]  A. V. D. Meer,et al.  Faculty Opinions recommendation of Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. , 2016 .

[93]  S. Hutchinson,et al.  Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.

[94]  M. Manns,et al.  All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study , 2014, The Lancet.

[95]  M. Alter,et al.  Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study , 2013, Hepatology.

[96]  I. Wilson,et al.  Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33 , 2012, Journal of Virology.

[97]  C. Stedman,et al.  O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE , 2014 .

[98]  I. Colle,et al.  Characteristics of patients with hepatitis B virus and hepatitis C virus dual infection in a Western European country: Comparison with monoinfected patients. , 2017, Clinics and research in hepatology and gastroenterology.

[99]  T. Hassanein,et al.  Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. , 2017, Journal of hepatology.

[100]  T. Asselah,et al.  Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results , 2013, Antiviral therapy.

[101]  P. Klenerman,et al.  The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals , 2011, The Journal of general virology.

[102]  K. Kowdley,et al.  Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection , 2017, Hepatology.

[103]  P. Marcellin,et al.  Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. , 2015, Journal of hepatology.

[104]  J. McKeating,et al.  Hepatitis C virus entry: beyond receptors , 2012, Reviews in medical virology.

[105]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[106]  V. Garg,et al.  Pharmacokinetic Interaction between Telaprevir and Methadone , 2013, Antimicrobial Agents and Chemotherapy.

[107]  K. Reddy,et al.  GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.

[108]  M. Hellard,et al.  Injecting drug use in low and middle‐income countries: Opportunities to improve care and prevent harm , 2017, Journal of viral hepatitis.

[109]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[110]  Heino Stöver,et al.  Prison-based needle and syringe programmes (PNSP) – Still highly controversial after all these years , 2016 .

[111]  Brian L. Pearlman,et al.  Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. , 2017, Gastroenterology.

[112]  K. Sherman,et al.  HIV/hepatitis C coinfection natural history and disease progression. , 2011, Current opinion in HIV and AIDS.

[113]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[114]  O. Weiland,et al.  ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.

[115]  P. Klenerman,et al.  HCV–HIV Coinfection: Simple Messages from a Complex Disease , 2007, PLoS medicine.

[116]  G. Dusheiko.  Hepatitis C in the EU: setting the terms for elimination. , 2017, The lancet. Gastroenterology & hepatology.

[117]  Qilong Yi,et al.  Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis , 2008, AIDS.

[118]  M. Manns,et al.  The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. , 2014, Gastroenterology.

[119]  B. Strom,et al.  A National Strategy for the Elimination of Viral Hepatitis Emphasizes Prevention, Screening, and Universal Treatment of Hepatitis C , 2017, Annals of Internal Medicine.

[120]  G. Dore,et al.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.

[121]  Rebecca R. Gray,et al.  A New Evolutionary Model for Hepatitis C Virus Chronic Infection , 2012, PLoS pathogens.

[122]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[123]  D. Brainard,et al.  sofosbuvir in Combination With Pegifn and Ribavirin for 12 Weeks Provides High Svr Rates in Hcv-infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the Lonestar-2 Study : lb-4 , 2013 .

[124]  H. Mota-Filipe,et al.  Long-Term Effect of the Portuguese Universal Access Program to New Generation Direct-Acting Antivirals for the Treatment of Hepatitis C , 2016 .

[125]  E. Verna,et al.  Cholestatic hepatitis C following liver transplantation: An outcome‐based histological definition, clinical predictors, and prognosis , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[126]  A. Phillips,et al.  Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study , 2014, Journal of the International AIDS Society.

[127]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[128]  O. Laeyendecker,et al.  Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. , 2015, The Lancet. Infectious diseases.

[129]  W. McGuire,et al.  Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. , 2006, The Cochrane database of systematic reviews.

[130]  J. Honegger,et al.  Hepatitis C Virus in Pregnancy , 2013, American Journal of Perinatology.

[131]  T. Asselah,et al.  Interferon free therapy with direct acting antivirals for HCV , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[132]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[133]  A. Lok,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[134]  H. Yoshiji,et al.  Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. , 2017, Gastroenterology.

[135]  D. Webster,et al.  Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and Ribavirin , 2013, International journal of STD & AIDS.

[136]  M. Manns,et al.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.

[137]  M. Egger,et al.  Hepatitis C virus transmission among human immunodeficiency virus‐infected men who have sex with men: Modeling the effect of behavioral and treatment interventions , 2016, Hepatology.

[138]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[139]  H. Mo,et al.  Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885 , 2013, Antimicrobial Agents and Chemotherapy.

[140]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[141]  M. Manns,et al.  Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study , 2006, Hepatology.

[142]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[143]  Y. F. Ibrahim,et al.  Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction , 2017, Journal of translational internal medicine.

[144]  R. Garfein,et al.  Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. , 2002, American journal of epidemiology.

[145]  N. Gruener,et al.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.

[146]  B. Gazzard,et al.  Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin , 2005, Journal of acquired immune deficiency syndromes.

[147]  M. Hellard,et al.  Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model , 2016, Gut.

[148]  G. Waris,et al.  Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma , 2017, The Journal of Biological Chemistry.

[149]  S. Chevaliez.  Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance. , 2011, Clinics and research in hepatology and gastroenterology.

[150]  X. Forns,et al.  An interferon-free antiviral regimen for HCV after liver transplantation. , 2014, The New England journal of medicine.

[151]  V. Soriano,et al.  Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV , 2013, Annals of Internal Medicine.

[152]  Ulysses Diva,et al.  Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. , 2012, The Lancet. Infectious diseases.

[153]  S. Hill,et al.  Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis , 2016, PLoS medicine.

[154]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[155]  J. Rockstroh,et al.  Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. , 2017, The lancet. Gastroenterology & hepatology.

[156]  J. Pawlotsky,et al.  A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C , 2012, Journal of viral hepatitis.

[157]  P. Simmonds,et al.  Nonprimate Hepaciviruses in Domestic Horses, United Kingdom , 2012, Emerging infectious diseases.

[158]  R. Marinho,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[159]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[160]  Daniel J. Wilson,et al.  A Modified RNA-Seq Approach for Whole Genome Sequencing of RNA Viruses from Faecal and Blood Samples , 2013, PLoS ONE.

[161]  M. Murcko,et al.  Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide , 1996, Cell.

[162]  J. Rich,et al.  Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis , 2013, Hepatology.

[163]  Geoffrey Dusheiko,et al.  Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. , 2017, The lancet. Gastroenterology & hepatology.

[164]  Joseph Eliahoo,et al.  Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men , 2010, Gut.

[165]  I. Água-Doce,et al.  Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay , 2013, Journal of medical virology.

[166]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[167]  M. Manns,et al.  Treatment With LedipasvirSofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection , 2016, Annals of Internal Medicine.

[168]  P. Easterbrook,et al.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[169]  A. Neumann,et al.  Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study , 2012, BMC Gastroenterology.

[170]  O. Pybus,et al.  The Epidemic Behavior of the Hepatitis C Virus , 2001, Science.

[171]  M. Manns,et al.  Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[172]  G. Dore,et al.  Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression , 2008, Hepatology.

[173]  M. Manns,et al.  Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. , 2015, Gastroenterology.

[174]  C. Datz,et al.  A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. , 2013, Journal of hepatology.

[175]  Brian L. Pearlman,et al.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.

[176]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[177]  H. Mo,et al.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.

[178]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[179]  J. Goedert,et al.  Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C Virus Infection: Data From Multiple Cohorts , 2013, Annals of Internal Medicine.

[180]  M. Ramgopal,et al.  12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[181]  Brian L. Pearlman,et al.  Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. , 2017, Gastroenterology.

[182]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. , 2017, Gastroenterology.

[183]  Jean-Michel Pawlotsky,et al.  Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.

[184]  M. Polis,et al.  Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. , 2015, The Lancet. Infectious diseases.

[185]  Oliver Lenz,et al.  Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial , 2014, The Lancet.

[186]  R. Pondé.  Enzyme-linked immunosorbent/chemiluminescence assays, recombinant immunoblot assays and nucleic acid tests in the diagnosis of HCV infection , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[187]  E. Poveda,et al.  Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor , 2012, Antiviral therapy.

[188]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[189]  V. Ausina,et al.  Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[190]  R. Malekzadeh,et al.  Strategies to manage hepatitis C virus infection disease burden – volume 3 , 2015, Journal of viral hepatitis.

[191]  P. Easterbrook,et al.  Hepatitis C: global epidemiology and strategies for control. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[192]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[193]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[194]  X. Forns,et al.  Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. , 2014, Gastroenterology.

[195]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[196]  A. Kiss,et al.  Viral hepatitis: New data on hepatitis C infection , 2008, Pathology & Oncology Research.

[197]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[198]  M. Manns,et al.  Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study , 2013, Hepatology.

[199]  A. Rodger,et al.  Transmission of HCV in HIV-positive populations. , 2011, Current opinion in HIV and AIDS.

[200]  P. Massip,et al.  Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults , 2009, AIDS.

[201]  E. Singer,et al.  Neurocognition in Individuals Co-Infected with HIV and Hepatitis C , 2008, Journal of addictive diseases.

[202]  T. Hassanein,et al.  P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION , 2014 .

[203]  A. Grulich,et al.  Sexual transmission of hepatitis C virus among gay and bisexual men: a systematic review. , 2017, Sexual health.

[204]  Jean-Michel Pawlotsky,et al.  Treatment failure and resistance with direct‐acting antiviral drugs against hepatitis C virus , 2011, Hepatology.

[205]  E. Lawitz,et al.  The HCV NS5B nucleoside and non-nucleoside inhibitors. , 2011, Clinics in liver disease.

[206]  K. Mounzer,et al.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. , 2014, JAMA.

[207]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[208]  C. Rice,et al.  Characterization of a canine homolog of hepatitis C virus , 2011, Proceedings of the National Academy of Sciences.

[209]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[210]  C. Stedman,et al.  Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. , 2015, Gastroenterology.

[211]  S. Naggie,et al.  Treatment of Genotype 1 HCV Infection in the HIV Coinfected Patient in 2014 , 2013, Current HIV/AIDS Reports.

[212]  B. Bacon,et al.  Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network , 2017 .

[213]  The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia , 2016, Virology Journal.

[214]  K. Reddy,et al.  Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus , 2015, Hepatology.

[215]  P. Klotman,et al.  The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis , 2008, AIDS.

[216]  J. Hoofnagle,et al.  The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes , 2011, Alimentary pharmacology & therapeutics.

[217]  J. Ghrayeb,et al.  Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection , 2003, The Journal of experimental medicine.

[218]  K. Stone.  Global state of harm reduction 2016. , 2016 .

[219]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[220]  S. Pol,et al.  Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. , 2017, The lancet. Gastroenterology & hepatology.

[221]  A. Folgori,et al.  Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man , 2012, Science Translational Medicine.

[222]  C. Tural,et al.  Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus , 2009, Hepatology.

[223]  P. Marcellin,et al.  The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[224]  T. Hassanein,et al.  Management of the patient with SVR. , 2016, Journal of hepatology.

[225]  P. Faure,et al.  Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. , 2014, Journal of hepatology.

[226]  Minqiao Zheng,et al.  A personalized approach identifies disturbed pathways and key genes in hepatitis C virus-cirrhosis with hepatocellular carcinoma. , 2016, European review for medical and pharmacological sciences.

[227]  Martin Fisher,et al.  Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. , 2009, Gastroenterology.

[228]  F. Mcphee,et al.  1210 PRE-EXISTENCE, EMERGENCE AND PERSISTENCE OF HCV GENOTYPE 4 NS5A RESISTANCE VARIANTS FROM THE PHASE 2B COMMAND-1 STUDY: DACLATASVIR PLUS PEGINTERFERON-alfa/ RIBAVIRIN IN TREATMENT-NAIVE PATIENTS , 2013 .

[229]  M. Guarino,et al.  Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. , 2017, Journal of hepatology.